Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Can-Fite BioPharma Ltd
CANF | US
2.92
USD0
0%
CANF | US
Loading StockChartView...
About Can-Fite BioPharma Ltd
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
13/04/2026
Close
2.92
Open
3.02
High
3.10
Low
2.91
Can-Fite BioPharma Ltd. a clinical-stage biopharmaceutical company develops small molecule therapeutic products for the treatment of cancer liver inflammatory diseases and erectile dysfunction. The company's lead drug candidate Piclidenoson which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602 which is in pre-clinical trial for the treatment of erectile dysfunction. In addition the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop manufacture and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer inflammatory autoimmune and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva Israel.
View LessCANF | US
Risk
42.5
Sharpe
-1.14
Luna's Score
34/100
Recommendation
Sell
Luna says (CANF | US)
What's Working
Low Market Beta (-0.4 to 0.8)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
37.2%1 month
42.5%3 months
85.2%6 months
101.6%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
4.21
Price to book
7.06
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
0.10
Ent. to rev.
15.75
PEG
-
Other Fundamentals
EBITDA
-7.79M
MarketCap
17.80M
MarketCap(USD)
17.80M
Div. yield
-
Op. margin
-1.30K
Erngs. growth
-
Rev. growth
-19.40
Ret. on equity
-157.62
Short ratio
2.51
Short perc.
5.94
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.33
Range1M
0.81
Range3M
7.50
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.15
Price X volume
125.00K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.10 | 0.53 | Cheaper |
| Ent. to Revenue | 15.75 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 7.06 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 85.17 | 72.80 | Par |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 17.80M | 3.66B | Emerging |
